Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Ambulatory Infusion Center Market, by Therapy Type (Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis,  Clotting Factor Replacement Therapy, and Others), by Application (Chronic Inflammatory Disorders, Neurological Disorders, Cancers, Nutrition Support, and Gastro-intestinal Disorders), by Distribution Channel (Hospital, Clinics, and Home Infusion), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 47,013.5  million in 2020 and is expected to exhibit a CAGR of 9.0% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key companies focusing on strategies such as expanding ambulatory infusion service facility for patients is expected to drive the global ambulatory infusion center market. For instance, in February 2020, Morris Hospital & Healthcare Centers, announced that they will provide ambulatory infusion health services, in its newly renovated infusion therapy center. The center will provide ambulatory infusion to patients who require outpatient infusion therapy treatments, including blood transfusions, intravenous (IV) antibiotics and medications, hydration, and injection services.

Global Ambulatory Infusion Center Market – Impact of Coronavirus (COVID-19)

  • The COVID-19 pandemic have negatively impacted ambulatory infusion center market. Therefore, government regulatory bodies are taking initiatives to decrease the risk of spread of COVID-19 infections while carrying out infusion procedures.
  • In order to manage patients undergoing ambulatory infusion procedures during the COVID-19 pandemic, various government regulatory bodies are taking initiatives to combat various difficulties faced by patients such as shortage of personal healthcare attendant and health care treatments for individuals suffering from cancer, bowel disorders during the COVID-19 pandemic. According to the US National Library of Medicine report published in September 2020, stated safety precaution guidelines for patients undergoing ambulatory infusion for various diseases such as cancers and gastrointestinal disorders, the guidelines are as follows;
  • Pre-screen for covid-19 symptoms/exposure 24-48 hours before scheduled infusion
  • If positive SARS-COV-2 infection is detected, infusion needs to be scheduled only after a negative swab, or two weeks after symptoms resolve and patients must come unaccompanied when possible.

Browse 33 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on “Global Ambulatory Infusion Center Market, by Therapy Type (Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy, and Others), by Application (Chronic Inflammatory Disorders, Neurological Disorders, Cancers, Nutrition Support, and Gastro-intestinal Disorders), by Distribution Channel (Hospital, Clinics, and Home Infusion), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in the global ambulatory infusion center market, click the link below:

https://www.coherentmarketinsights.com/market-insight/ambulatory-infusion-center-market-4318

The market is expected to witness significant growth during the forecast period, owing to key players focusing on raising funds to focus on service expansion to develop ambulatory infusion centers for treatment of various disorders such as bleeding disorders, cancer, and others. For instance, in November 2019, InFuse Holdings Inc, announced that they have received Series A funding from BroadOak Capital Partners to expand their network of high-quality, cost-effective infusion centers throughout Ohio and the Midwest. The initial funding will be used to acquire Cincinnati-based Horizon Infusions and provide growth capital for its expansion. 

Key Takeaways of the Global ambulatory infusion center Market:

  • The global ambulatory infusion center market is expected to exhibit a CAGR of 9.0% during the forecast period, owing to key companies focusing on raising funds to focus on strategies such as service expansion to develop ambulatory infusion centers for treatment of various disorders such as bleeding disorders, cancers, and others. For Instance, October 2019, PURE Healthcare, the parent company of PURE Infusion Suites, an innovator in the ambulatory infusion space, today announced a new round of funding of $40M to expand the national footprint of PURE Infusion Suites. The pure infusion suites will provide ambulatory infusion services for people suffering from cancers.
  • Among therapy type, blood product Infusion segment is estimated to hold major market share in the global ambulatory infusion center market during the forecast period, owing to increasing prevalence of blood disorders such as anemia in individuals. According to US National Library of Medicine, report published in 2019, stated that approximately 1.62 billion of people are suffering from anemia globally, in year 2019.
  • Among application, cancers segment is estimated to hold major market share in the global ambulatory infusion center market during the forecast period, owing to increasing prevalence of various cancers such as lung cancer, blood cancer, globally.
  • Key players operating in the global ambulatory infusion center market include Option Care Health, PharmaScript, Cleveland Clinic, Stoughton Health, Coram CVS, Hattiesburg Clinic, UnitedHealth Group, UK HealthCare, CHI Health, PharMerica, Beacon Health System, Inc., Arnot Health, Inc., IVX Health, and Precision Healthcare.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.